Member Info for Bermudashorts

Compoundinterest,

No, I haven't been able to find any other AIM listed companies, although of course it's possible that they are holding below the notifiable threshold on one or two. I have come across some privately held UK companies amongst Redmile's portfolio (past and present) and if you have the time, it's worth a quick look to appreciate the quality of the companies they invest in.

ACHILLES THERAPEUTICS
This is a top pedigree spin out from UCL and the Francis Crick Institute to commercialise the work of Prof. Charles Swanton and others. Wellcome Trust and Cancer Research heavily involved through their investment vehicle Sycona. Redmile invested in September 2019.
https://achillestx.com/

NIGHTSTAR THERAPEUTICS
University of Oxford spin out to commercialise gene therapy work of Robert MacLaren, Prof. of ophthalmology. Although it was nasdaq listed, I believe Redmile invested when it was still privately held. The company was sold to Biogen for $800m.

OXFORD NANOPORE
Another Oxford University spin out selling DNA/RNA sequencing products and founded by Prof. Hanan Bayley.
https://nanoporetech.com/

These are just some that I happen to have read about and I'm sure there are others but you get the gist.

Just also wanted to make a quick point about Redx. The path that led Redmile to taking over Redx was complex and unique and although they hold 92% of the stock, it remains an AIM listed company. I don't think Redmile's interest was driven by any desire to start taking over and running biotech. companies but was more about giving the Redx the funding it needed to optimise the potential value of its pipeline. They had already been forced to sell off a potential blockbuster at bargain basement prices and hopefully now have some financial stability. Worth noting that Redmile often work with partners and in Redx's case it was Sofinnova so might be worth keeping an eye on what they're up to.

All IMO etc.

OK sorry - hard to keep up :)

Ray,

You think it may be cancelled again?

G_T_F_C

Thanks for the reminder

Trinity Delta were appointed by Scancell who pay them for their research. You therefore have to assume that Lindy Durrant is more than happy with their qualifications and that Scancell are happy with their output.

I believe they do a a good job. Their research notes are comprehensive, well written, easy to understand and a great starting point for any new shareholders, not least because we know they have direct access to Scancell. As has been said, they use standard industry valuation methods which means that they don't attribute any monetary value to preclinical assets but that's not the same thing at all as saying Scancell's preclinical products are worthless . The potential value of Avidimab is clearly explained in the text.

Lack of independent analyst coverage is a real problem for AIM listed bios in the UK. We should see Trinity Delta's research for what it is - an attempt by Scancell to plug the gap and provide coverage aimed at retail investors. I really don't see what the issue is.

Ivy,

It's an OBN event and as you say, it's local. I don't think it reflects Scancell's ambitions and is likley to be one of those that he's almost duty bound to attend. Nothing groundbreaking and tbh the main reason I posted was to move the discussion along. Worked well lol!

Apparently the Government is lifting restrictions on events from the 1st October meaning that it will be possible once again to hold conferences in person rather than virtually. I assume there will be rules re. distancing, masks etc. Cliff Holloway is attending what must be one of the very first 'in person' conferences, BioForward 2020 in Oxford on 5th October.

Let's hope he listens carefully to the session at 14.50.

https://bioforward.co.uk/

Thanks Ivy, had just assumed you'd have access through work but can understand you'd not want to mix work and investing. Will take another look in view of your comments.

Ray Pointer,

BioNTech?

Ivy,

Assumed LD's presentation was at an industry only conference, didn't realise it was open to members of the public.

LL - yes well spotted

Ray - yes, the focus on colorectal cancer is interesting. It was an area of special interest for LD earlier in her career - google Lindy Durrant and colorectal cancer and you'll see the beginnings of ImmunoBody emerging.

Another research paper has been published on the role of PAD2 and PAD4 enzymes in colorectal cancer and their potential use as early markers of progression. PAD enzymes are responsible for citrullination . Conclusion:-

'However, cancer vaccines targeting citrullinated vimentin and/or enolase maybe a good therapy for CRC
patients expressing high levels of PAD enzymes'

You can download the full pdf. here

https://www.medrxiv.org/content/10.1101/2020.08.14.20174920v1

WTP

Not necessarily, they're just their top 50 holdings and I suspect they're taken from SEC filings so are possibly also just the US listed holdings. In terms of spread of holdings, the charts on the first link are probably more useful.

rats,

re. Your earlier post, you're right, when the first collaboration was announced, they made no mention of the location of the collaborator but the recent proposed placing RNS confirmed that it was a European company :-

'The Company has entered into three non-exclusive research agreements with leading antibody technology companies in Europe, the USA and China to evaluate the Company's anti-TaG mAbs including those enhanced with the AvidiMab™ technology.'

I have been meaning to post a little bit about Redmile for a while and below is a copy the main part of a post I've just put up on ADVFN. I know somebody asked about them the other day, sorry but I can't remember who. Just wanted to say that I wasn't ignoring you but was out and about at the time and didn't have access to my laptop or the internet!

Interest from biotech. funds has been sorely lacking to date but Scancell now seem to have landed themselves a high calibre, big player and their involvement has the potential to be a turning point IMO. Redmile are a high quality and respected healthcare specialist with total AUM of around $7 billion. Their investment strategy leans towards longer term and is very much based on fundamentals. They aim to spot product cycles, trends and changes to the fundamental outlook of companies before the rest of the market. According to their brochure:-

'the Firm utilizes a number of different avenues to provide information leading to an investment decision. The following are sources for the Firm’s ideas: (a) contacts with physicians; (b) focus outside of the United States; (c) dialogue with companies; (d) attendance at medical conferences; (e) meetings with private companies; and (f)regular dialogue within the team.'

You can see from the first link below that the vast majority of their investments are in US companies with holdings of between $1m and $100m. Perhaps more interesting is the second link which lists their top 50 investments. You can click the tickers for more information about each company and can see the relationship between the size of the holding and the market cap of each one. Even the companies at the bottom of the list have market caps over $1 billion so Scancell has a way to go to make it onto that list!

I've also added a link to the bio for Redmile founder and fund manager Jeremy Green.

So that's a basic summary of the group and of course we don't know which particluar fund(s) have invested in Scancell. As this post is probably already too long, I'll put up another post with some suggestions on what may have brought Scancell to their attention.

Https://docoh.com/company/1425738/redmile-group-llc/holdings-history

Https://docoh.com/company/1425738/redmile-group-llc

Https://agln.aspeninstitute.org/profile/4607

The Clinical Trials Register was updated yesterday for the MRx0518 / Keytruda combination study to show that the additional trial centres are all now up, running and actively recruiting.

Reassuring that in the middle of a global pandemic 4D Pharma have managed to expand the number of centres for this trial and this should increase the speed of recruitment in due course.

https://clinicaltrials.gov/ct2/show/NCT03637803?term=4d+pharma&draw=2&rank=5

alphabravo, agree an excellent presentation and well worth a listen.

Meanwhile Amryt feature in this article asking why some European biotechs are listing on NASDAQ without an IPO.

“Amryt has broken the mold of the traditional biotech model where typically a biotech has no revenues and burns cash,” he told me. “We have revenue-generating products and are cash generative. We therefore didn’t need to raise money when listing.”

https://www.labiotech.eu/finance/ipo-biotech-europe-spac/?utm_source=twitter&utm_medium=social&utm_campaign=SocialWarfare

Inanaco

I don't need to provide a mathematical model to know that I own a smaller percentage of Scancell today than I did last week and that my holding has been diluted. I am sure ONW would agree. The value of that holding and any increase in the potential value is a completely different point - that relates to the impact of the funding and the dilution, but nobody can deny it has taken place apart from you it seems.

I give up completely - absolutely pointless

Following on from my previous post, yet more research on the FG88 glycan has been published today, this time involving researchers from RMIT University, Australia.

The paper, 'Molecular and structural basis for Lewis glycan recognition by a cancer-targeting antibody' was published in the peer-reviewed Biochemical Journal. Haven't had a chance to download the full pdf. and suspect that it's way beyond my level of understanding in any case. However, further evidence that plenty is going on with these mAbs.

https://portlandpress.com/biochemj/article/doi/10.1042/BCJ20200454/226072/Molecular-and-structural-basis-for-Lewis-glycan

Crackin - ha ha

Chelsea - agree

Inanaco - have a look at Scancell's website which has now been updated to reflect recent events. Calculus didn't take part in the OO and still hold 49,844,165 shares. Before this round of funding they owned 10.71% of the Company but today the same amount of shares gives them just 7.92% - their holding (not the IP) has been diluted. FACT. Now would be a good time to accept that dilution has taken place, put the funding behind us and move on.